{"nctId":"NCT00631371","briefTitle":"Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","startDateStruct":{"date":"2008-04"},"conditions":["Renal Cell Carcinoma"],"count":791,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Bevacizumab","Drug: Temsirolimus"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab","Drug: Interferon-Alfa 9MU"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Torisel"]},{"name":"Temsirolimus","otherNames":[]},{"name":"Bevacizumab","otherNames":[]},{"name":"Interferon-Alfa 9MU","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC)\n* Majority component of conventional clear-cell type is mandatory\n* At least 1 measurable lesion (per RECIST)\n\nExclusion Criteria:\n\n* Prior systemic treatment for RCC\n* Evidence of current or prior central nervous system (CNS) metastases\n* Cardiovascular disease\n* Pregnant or nursing women\n* Additional criteria applies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS): Independent-Assessment","description":"PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by independent imaging reviewers using Response Evaluation Criteria in Solid Tumors (RECIST) criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS): Investigator-Assessment","description":"PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by investigator imaging reviewers using RECIST criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response (Complete Response/Partial Response): Independent-Assessment","description":"Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"27.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death due to any cause, censored at the last date known alive. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"25.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":184,"n":393},"commonTop":["Proteinuria","Pyrexia","Decreased appetite","Hypertension","Fatigue"]}}}